The team
Management
Dr. Stéphane Huberty is the founder and Chief Executive Officer of CuraVac.
Dr. Huberty has over 30 years experience as a successful entrepreneur and manager. He also founded and is CEO of IDEAS in Belgium, a company specializing in CAD/CAM production of customized orthopaedic and normal footwear for which he was awarded the Young Entrepreneur of the Year award in 1993.
He is a medical doctor and graduate of the Catholic University of Louvain (UCL), Belgium. During his medical studies, he specialized in the use of computers in medicine and worked as a research fellow at UCLA. He has studied the research of Professor Blalock for personal reasons, as a sufferer from Myasthenia Gravis.
Research
Dr. Jean-Paul Prieels, Ph.D, served as a Senior Vice President of Research and Development at GlaxoSmithKline Biologicals (now GSK Vaccines) until January 2011.
Dr. Prieels joined GlaxoSmithKline Biologicals in 1987 as an Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart, Belgium. His career spans from basic research to process and product development.
He was instrumental in developing several commercially available vaccines, such as rotavirus, human papilloma virus (HPV), pneumococcal conjugates and others. He served as Head of Research at GSK Vaccines.
He serves as a Director of Vaximm AG. Since 2007, he has been a Member of the Scientific Advisory Board of the Singapore Bioprocessing Technology Institute. He serves as Chairman of the Board at Immune Health and he was also a Board member of Henogen from 2000 to 2008.
Development
Nicolas Havelange is the Chief Operating Officer of CuraVac.
Nicolas is a pharmaceutical biotechnology expert with 25 years experience in biopharmaceutical process developement and manufacturing in mammalian and microbial expression systems, mRNA and synthetic peptides. He offers consulting and operational services to funders, foundations, biotech and pharmaceutical companies in process development, cGMP manufacturing, CMOs management, project management and business development.
As a CMC consultant for CEPI (Coalition for Epidemic Preparedness Innovation), he participated in several Covid-19 vaccine development projects as a CMC lead and CMC subject matter expert for mRNA vaccines.
He held diverse positions at SmithKline Beecham Biologicals (now GSK Vaccines) and has participated in the launch and growth of several succes stories such as Henogen (now Novasep-Henogen), Artelis/ATMI (now Pall LifeSciences), European Vaccine Initiative and other promising biotech companies such as Bioxodes and CuraVac.
He holds a Master in Chemical Engineering from Ecole Polytechnique de l’Université Libre de Bruxelles (ULB) and a Master in Molecular Biology and Biotechnology also from ULB.
Administration
Leone Flynn is in charge of the administration at CuraVac.
Leone Flynn has been the Chief Administrative Officer at CuraVac since its creation in 2002. Ms Flynn is also the founder and manager of PodoProductions, a custom foot orthotic milling service for podiatrists. Ms Flynn holds a degree in International Commerce from University College Dublin and an executive master in Marketing from the Solvay Business School, Brussels.
Investor Relations Advisor
Alexandra is a dynamic and passionate communications specialist with a solid understanding of financial markets, bringing 25 years of combined international experience across sectors including pharmaceutical, automotive, banking, and insurance in New York, London, and Europe.
With over a decade of specialized focus in the biotech and pharmaceutical industries, she supports CuraVac by leveraging her expertise in IR strategy and communication, advancing the company’s fundraising efforts. Alexandra holds an M.B.A. in International Management from Fordham University in New York and a Bachelor’s degree in International Business from Loyola College in Maryland.
Project Manager
With more than 20 years of experience in the pharmaceutical field, Samuel began his career in the quality control laboratories of large companies such as Solvay, Pfizer and Laborelec.
In 2006, he joined the startup Artelis, active in the fields of vaccines and cell therapy. He participates in the creation and implementation of single-use bioreactors and mixers for which he is co-owner of a patent filed in 2007.
Samuel joined CuraVac in 2020 as a project manager as part of the Myasterix program.
